<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01888874</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG0634-CL-203 (DARWIN1)</org_study_id>
    <secondary_id>2012-003635-31</secondary_id>
    <nct_id>NCT01888874</nct_id>
  </id_info>
  <brief_title>Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)</brief_title>
  <acronym>DARWIN1</acronym>
  <official_title>Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks in Combination With Methotrexate to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants suffering from active rheumatoid arthritis despite continued treatment with&#xD;
      methotrexate were evaluated for improvement of disease activity (efficacy) when taking&#xD;
      GLPG0634 (3 different doses - 50 milligram [mg], 100 mg and 200 mg daily -, each evaluated as&#xD;
      once daily [QD] and twice daily [BID] regimen) or matching placebo for 24 weeks.&#xD;
&#xD;
      •During the course of the study, patients were also examined for any side effects that could&#xD;
      occur (safety and tolerability), and the amount of GLPG0634 present in the blood&#xD;
      (Pharmacokinetics) as well as the effects of GLPG0634 on disease- and mechanism of&#xD;
      action-related parameters in the blood (Pharmacodynamics) were determined. Also, the effects&#xD;
      of different doses and dose regiments of GLPG0634 administration on participants' disability,&#xD;
      fatigue, and quality of life were evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Treatment duration was 24 weeks in total.&#xD;
&#xD;
        -  However, at Week 12, participants on placebo who did not achieve a 20% improvement in&#xD;
           swollen joint count(SJC66) and tender joint count (TJC68) were re-randomized&#xD;
           (automatically via interactive voice/web response [IXRS]) to treatment to receive&#xD;
           GLPG0634 100 mg QD or 50 mg BID doses in a blinded fashion, participants on 50 mg QD who&#xD;
           had not achieved a 20% improvement in SJC66 and TJC68 were assigned to 100 mg QD and&#xD;
           participants on 25 mg BID. who did not achieve a 20% improvement in SJC66 and TJC68 were&#xD;
           assigned to 50 mg BID. All continued the study until Week 24.&#xD;
&#xD;
        -  Participants in the other groups maintained their randomized treatment until Week 24.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 17, 2013</start_date>
  <completion_date type="Actual">May 14, 2015</completion_date>
  <primary_completion_date type="Actual">February 18, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving an American College of Rheumatology (ACR) 20 Response at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The American College of Rheumatology (ACR) response is a measurement of improvement in multiple disease assessment criteria. The ACR20 response is defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in tender TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain visual analog scale (VAS) (taken from the Health Assessment Questionnaire - Disability Index [HAQ-DI]), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used (ie, to impute a missing response, the participant was assumed to be a non-responder).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an ACR20 Response at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>ACR20 response was defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an ACR50 Response at Weeks 1, 2, 4, 8, 12, and 24</measure>
    <time_frame>Weeks 1, 2, 4, 8, 12, and 24</time_frame>
    <description>ACR50 response was defined as: 1) ≥ 50% improvement from baseline in SJC66, and 2) ≥ 50% improvement from baseline in TJC68, and 3) ≥ 50% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI) 2. Patient's Global Assessment of Disease Activity VAS 3. Physician's Global Assessment of Disease Activity VAS 4. Total HAQ-DI score 5. CRP. Non-responder imputation was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an ACR70 Response at Weeks 1, 2, 4, 8, 12, and 24</measure>
    <time_frame>Weeks 1, 2, 4, 8, 12, and 24</time_frame>
    <description>ACR70 response: 1) ≥ 70% improvement from baseline in SJC66, and 2) ≥ 70% improvement from baseline in TJC68, and 3) ≥ 70% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR N% Improvement (ACR-N) Response at Weeks 1, 2, 4, 8, 12, and 24</measure>
    <time_frame>Weeks 1, 2, 4, 8, 12, and 24</time_frame>
    <description>The ACR-N is the smallest percentage improvement in swollen and tender joints and the median of the remaining 5 core parameters, and is expected to be more sensitive to change than the ACR20, ACR50 or ACR70. It is a number varying between 0 and 100, with higher numbers indicating less severity of symptoms. Last observation carried forward (LOCF) algorithm was used (ie, to impute a missing value, the last preceding nonmissing value was used).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Disease Activity Score 28 Joints Corrected for CRP (DAS28 (CRP)) European League Against Rheumatism (EULAR) Response at Weeks 1, 2, 4, 8, 12, and 24</measure>
    <time_frame>Weeks 1, 2, 4, 8, 12, and 24</time_frame>
    <description>DAS28 (CRP) was categorized into EULAR response categories (none, moderate, good) as follows: None = Actual DAS28 (CRP) ≤ 3.2, &gt; 3.2 to ≤ 5.1, or &gt; 5.1 AND Improvement in DAS28 (CRP) from baseline ≤ 6.0 or &gt; 0.6 to ≤ 1.2; Moderate = Actual DAS28 (CRP) ≤ 3.2 AND Improvement in DAS28 (CRP) from baseline &gt; 0.6 to ≤ 1.2, Actual DAS28 (CRP) &gt; 3.2 to ≤ 5.1 or &gt; 5.1 AND Improvement in DAS28 (CRP) from baseline &gt; 1.2, or Actual DAS28 (CRP) &gt; 3.2 to ≤ 5.1 AND Improvement in DAS28 (CRP) from baseline &gt; 0.6 to ≤ 1.2; Good = Actual DAS28 (CRP) ≤ 3.2 AND Improvement in DAS28 (CRP) from baseline &gt; 1.2. LOCF algorithm was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving ACR/EULAR Remission at Weeks 2, 4, 8, 12, and 24</measure>
    <time_frame>Weeks 2, 4, 8, 12, and 24</time_frame>
    <description>A participant's disease activity status can be defined as being in remission when scores on the TJC28, SJC28, CRP (actual value in mg/dL) and Patient Global Assessment of Disease Activity (cm) are all ≤ 1. Non-responder imputation was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 1, 2, 4, 8, 12, and 24</measure>
    <time_frame>Baseline and Weeks 1, 2, 4, 8, 12, and 24</time_frame>
    <description>The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, Patient Global Assessment of Disease Activity (in cm), Physician's Global Assessment of Disease Activity (in cm), and CRP (mg/dL). The SDAI was categorized as follows:&#xD;
• High disease activity: SDAI &gt; 26 • Moderate disease activity: 11 to 26 • Low disease activity: 3.3 to 11 • Remission: ≤ 3.3. LOCF algorithm was used. The SDAI total score ranges from 0 to approximately 86.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 1, 2, 4, 8, 12, and 24</measure>
    <time_frame>Baseline and Weeks 1, 2, 4, 8, 12, and 24</time_frame>
    <description>The CDAI is the SDAI modified to exclude CRP and is the sum of the 4 outcome parameters: TJC28, SJC28, Patient Global Assessment of Disease Activity (in cm), and Physician's Global Assessment of Disease Activity (in cm). The CDAI was be categorized as follows: • High disease activity: &gt; 22 • Moderate disease activity: 10 to 22 • Mild disease activity: 2.8 to 10 • Remission: ≤ 2.8. LOCF algorithm was used. The CDAI total score ranges from 0 to approximately 76.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life Using the Functional Assessment of Chronic Illness Therapy (FACIT) at Weeks 4, 12, and 24</measure>
    <time_frame>Baseline and Weeks 4, 12, and 24</time_frame>
    <description>FACIT-Fatigue scale is a 13-item questionnaire, each scored on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated that are scored reversely), the greater the fatigue. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score), with a higher score indicating a better quality of life. LOCF algorithm was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life Using the Short Form-36 (SF-36) Scores at Weeks 4, 12, and 24</measure>
    <time_frame>Baseline and Weeks 4, 12, and 24</time_frame>
    <description>The SF-36 is a 36-item questionnaire measuring 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health). Each domain score ranges from 0 (worst) to 100 (best), with higher scores reflecting better health-related functional status. Two summary scale scores were computed based on weighted combinations of the 8 domain scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). LOCF algorithm was used.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">599</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received GLPG0634 matching placebo capsules, orally, twice daily (BID) during Weeks 1 to 12. Participants who were responders (having at least 20 percent [%] improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 milligram (mg) once daily (QD) or 50 mg BID during Weeks 13 to 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG0634 50 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG0634 100 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG0634 200 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG0634 25 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG0634 50 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG0634 100 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG0634</intervention_name>
    <description>GLPG0634 capsules.</description>
    <arm_group_label>GLPG0634 100 mg BID</arm_group_label>
    <arm_group_label>GLPG0634 100 mg QD</arm_group_label>
    <arm_group_label>GLPG0634 200 mg QD</arm_group_label>
    <arm_group_label>GLPG0634 25 mg BID</arm_group_label>
    <arm_group_label>GLPG0634 50 mg BID</arm_group_label>
    <arm_group_label>GLPG0634 50 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  have a diagnosis of RA since at least 6 months and meeting the 2010 ACR/EULAR criteria&#xD;
             of RA and ACR functional class I-III,&#xD;
&#xD;
          -  have ≥6 swollen joints (from a 66 joint count) and ≥8 tender joints (from a 68 joint&#xD;
             count) at Screening and at Baseline,&#xD;
&#xD;
          -  Screening serum c-reactive protein ≥0.7 x upper limit of laboratory normal range&#xD;
             (ULN),&#xD;
&#xD;
          -  have received MTX for ≥6 months and have been on a stable dose (15 to 25 mg/week) of&#xD;
             MTX for at least 4 weeks prior to Screening and willing to continue on their current&#xD;
             regimen for the duration of the study. Stable doses of MTX as low as 10 mg/week are&#xD;
             allowed when there is documented evidence of intolerance or safety issues at higher&#xD;
             doses.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  current therapy with any disease-modifying anti-rheumatic drugs (DMARD) other than&#xD;
             MTX,&#xD;
&#xD;
          -  current or previous RA treatment with a biologic DMARD, with the exception of biologic&#xD;
             DMARDs administered in a single clinical study setting more than 6 months prior to&#xD;
             Screening (12 months for rituximab or other B cell depleting agents), where the&#xD;
             biologic DMARD was effective, and if discontinued, this should not be due to lack of&#xD;
             efficacy,&#xD;
&#xD;
          -  previous treatment at any time with a cytotoxic agent, other than MTX, before&#xD;
             Screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Galapagos Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheumatology Associates of North Alabama, PC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artho Care, Arthritis Care &amp; Research P.C.</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Research PLLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.V. Mehta MD Medical Corporation</name>
      <address>
        <city>Hemet</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Innovative TherapyDivision of Rheumatology, UCSD</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Medical Advances</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Valley Medical Center</name>
      <address>
        <city>Victorville</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infosphere Clinical Research, Inc.</name>
      <address>
        <city>West Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RASF Clinical Research Center</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millennium Research</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Resources</name>
      <address>
        <city>Venice</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Center of North GA</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Idaho Arthritis Center</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professional Research Network of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Treatment Center</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klein and Associates MD</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private practice</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physicians East</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Rheumatology Research PA</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Centers of Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions Inc</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crossroads Clinical Research, LLC</name>
      <address>
        <city>Victoria</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Rheumatology Associates, PLLC</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain State Clinical Research</name>
      <address>
        <city>Clarksburg</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atencion Integral en Reumatologa</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology OMI</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Reumatologico</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Medico CER</name>
      <address>
        <city>Quilmes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Asistencia Reumatologia Integral</name>
      <address>
        <city>San Fernando</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Médico Privado de Reumatología</name>
      <address>
        <city>Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Repatriation General Hospital</name>
      <address>
        <city>Daw Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University/ AKH Vienna/ Dep.of Rheumatology 6J</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St-Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Brugmann</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheuma Instituut</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liège</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Multiprofile Hospital for Active Treatment - Kaspela&quot; LTD</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Ruse AD</name>
      <address>
        <city>Ruse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Rheumatology MHAT</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Consultative Center &quot;Sveta Anna&quot; LTD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Transport Hospital &quot;Tsar Boris&quot; III</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Clinic</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional &quot;Guillermo Grant Benavente&quot;</name>
      <address>
        <city>Concepcion</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Terapias Oncologicas Providencia</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prosalud</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Someal SA</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clínica del Sur Freire</name>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Office</name>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral de Reumatologia de Caribe</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación del caribe para la investigación medica Fundación BIOS</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral de Reumatologia e Inmunologia SAS</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cirei Sas</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Idearg S.A.S.</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicity S.A.S.</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Arthritis Temprana S.A.S.</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Preventive Care SAS</name>
      <address>
        <city>Cundinamarca</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologie S.R.O</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ambulance Revmatologie a Interniho Lekarstvi</name>
      <address>
        <city>Kladno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicka ambulance</name>
      <address>
        <city>Praha-Nusle</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Plus, s.r.o.</name>
      <address>
        <city>Uherske Hradiste</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PV-Medical</name>
      <address>
        <city>Zlin</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Mitte, Rheumatologie Neue Therapien</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schlossparkklinik - Akad. Lehrkrankenhaus Charite</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Goethe-Universität</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis fuer Rheumatologie</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Ruhrgebiet</name>
      <address>
        <city>Herne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Especialidades Medicas</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Medica Especializada en Reumatologia</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Medica</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reuma S.A.</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reuma-Centro</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRC</name>
      <address>
        <city>Balatonfured</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Budai Irgalmasrendi Korhaz</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qualiclinic Ltd</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revita Clinic</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markhot Ferenc Korhaz</name>
      <address>
        <city>Eger</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Pandy Kalman Korhaz, Reumatologiai Osztaly</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Csolnoky Ferenc County Hospital</name>
      <address>
        <city>Veszprem</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M&amp;M Centre Ltd.</name>
      <address>
        <city>Adazi</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meda D</name>
      <address>
        <city>Daugavplis</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L. Atikes doktorats</name>
      <address>
        <city>Liepaja</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Bruninieku&quot; polyclinic</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arija's Ancane's Family Doctor</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios de Investigacion Basica y Clinica, SC</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arké Estudios Clínicos</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinstile, S.A. de C.V.</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de México</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelerium Clinical Research</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario José E. González</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Alta Especialidad en Reumatología e Investigación del Potosí, S.C.</name>
      <address>
        <city>San Luis Potosi</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMSP Institutul de Cardiologie</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Timaru Rheumatology Studies</name>
      <address>
        <city>Timaru</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Osteo-Medic s.c.</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silesiana Centrum Medyczne</name>
      <address>
        <city>Bytom</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medica Pro Familia Sp. z o.o. S.K.A.</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Plejady</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nowomed</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nzoz &quot;Dobry Lekarz&quot;</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Przychodnia Lekarska &quot;Eskulap&quot;</name>
      <address>
        <city>Skierniewice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NS ZOZ Medicus Bonus</name>
      <address>
        <city>Sroda Wielkopolska</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Powiatowy Zakrad Opieki Zdrowotnej w Starachowicach</name>
      <address>
        <city>Starachowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Nasz Lekarz</name>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMED Medical Center</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny we Wroclawiu</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I.M. Sechenov First Moscow State Medical University</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Rheumatology RAMS</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of Medicine and Dentistry</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital 5</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ryazan State Medical University</name>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital # 26</name>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vladimir Reg Clin Hosp</name>
      <address>
        <city>Vladimir</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofa</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Mostoles</name>
      <address>
        <city>Mostoles</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Luisa</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital #5</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>V. Gusak Institute of Urgent and Recovery Surgery</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital #13</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital #8</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Government Institution</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Outpatient Hospital of Deanyanskyy Distric</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central regional polyclinic of Pechersk District</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution Lutsk City Clinical Hospital</name>
      <address>
        <city>Lutsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>Moldova, Republic of</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Peru</country>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 26, 2013</study_first_submitted>
  <study_first_submitted_qc>June 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2013</study_first_posted>
  <results_first_submitted>October 26, 2020</results_first_submitted>
  <results_first_submitted_qc>October 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 17, 2020</results_first_posted>
  <disposition_first_submitted>April 18, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>April 18, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 17, 2016</disposition_first_posted>
  <last_update_submitted>October 26, 2020</last_update_submitted>
  <last_update_submitted_qc>October 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Methotrexate inadequate responders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 27, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT01888874/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 18, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT01888874/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at study sites in Europe, South America, North America, Australia, and New Zealand. The first participant was screened on 17 July 2013. The last study visit occurred on 14 May 2015.</recruitment_details>
      <pre_assignment_details>A total of 1255 participants were screened of which 599 participants were randomized into the study and only 594 participants were treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received GLPG0634 matching placebo capsules, orally, twice daily (BID) during Weeks 1 to 12. Participants who were responders (having at least 20 percent [%] improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 milligram (mg) once daily (QD) or 50 mg BID during Weeks 13 to 24.</description>
        </group>
        <group group_id="P2">
          <title>GLPG0634 50 mg QD</title>
          <description>Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.</description>
        </group>
        <group group_id="P3">
          <title>GLPG0634 100 mg QD</title>
          <description>Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.</description>
        </group>
        <group group_id="P4">
          <title>GLPG0634 200 mg QD</title>
          <description>Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.</description>
        </group>
        <group group_id="P5">
          <title>GLPG0634 25 mg BID</title>
          <description>Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.</description>
        </group>
        <group group_id="P6">
          <title>GLPG0634 50 mg BID</title>
          <description>Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.</description>
        </group>
        <group group_id="P7">
          <title>GLPG0634 100 mg BID</title>
          <description>Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (Baseline up to Week 12)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="82"/>
                <participants group_id="P3" count="85"/>
                <participants group_id="P4" count="86"/>
                <participants group_id="P5" count="86"/>
                <participants group_id="P6" count="85"/>
                <participants group_id="P7" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="78"/>
                <participants group_id="P4" count="80"/>
                <participants group_id="P5" count="77"/>
                <participants group_id="P6" count="80"/>
                <participants group_id="P7" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event and treatment failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with the study procedures</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 (Week 13 to Week 24)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53">Nonresponders from Placebo group moved to 100 mg QD(15 participants) and 50 mg BID(15 participants).</participants>
                <participants group_id="P2" count="57">Nonresponders from 50 mg QD group moved to 100 mg QD group (19 participants).</participants>
                <participants group_id="P3" count="112">Nonresponders from Placebo(15 participants) and 50 mg QD (19 participants) moved to 100 mg QD group.</participants>
                <participants group_id="P4" count="80"/>
                <participants group_id="P5" count="60">Nonresponders from 25 mg BID group moved to 50 mg BID group (17 participants).</participants>
                <participants group_id="P6" count="112">Nonresponders from Placebo(15 participants) and 25 mg BID(17 participants) moved to 50 mg BID group.</participants>
                <participants group_id="P7" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="104"/>
                <participants group_id="P4" count="78"/>
                <participants group_id="P5" count="57"/>
                <participants group_id="P6" count="109"/>
                <participants group_id="P7" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event and treatment failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliance with study medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all participants who were randomized and received at least one dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received GLPG0634 matching placebo capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20 percent% improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 mg QD or 50 mg BID during Weeks 13 to 24.</description>
        </group>
        <group group_id="B2">
          <title>GLPG0634 50 mg QD</title>
          <description>Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.</description>
        </group>
        <group group_id="B3">
          <title>GLPG0634 100 mg QD</title>
          <description>Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.</description>
        </group>
        <group group_id="B4">
          <title>GLPG0634 200 mg QD</title>
          <description>Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.</description>
        </group>
        <group group_id="B5">
          <title>GLPG0634 25 mg BID</title>
          <description>Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.</description>
        </group>
        <group group_id="B6">
          <title>GLPG0634 50 mg BID</title>
          <description>Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.</description>
        </group>
        <group group_id="B7">
          <title>GLPG0634 100 mg BID</title>
          <description>Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="86"/>
            <count group_id="B2" value="82"/>
            <count group_id="B3" value="85"/>
            <count group_id="B4" value="86"/>
            <count group_id="B5" value="86"/>
            <count group_id="B6" value="85"/>
            <count group_id="B7" value="84"/>
            <count group_id="B8" value="594"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" lower_limit="18" upper_limit="84"/>
                    <measurement group_id="B2" value="52.8" lower_limit="20" upper_limit="77"/>
                    <measurement group_id="B3" value="52.3" lower_limit="20" upper_limit="79"/>
                    <measurement group_id="B4" value="54.8" lower_limit="19" upper_limit="75"/>
                    <measurement group_id="B5" value="52.4" lower_limit="24" upper_limit="79"/>
                    <measurement group_id="B6" value="55.4" lower_limit="21" upper_limit="78"/>
                    <measurement group_id="B7" value="53.9" lower_limit="22" upper_limit="76"/>
                    <measurement group_id="B8" value="53.4" lower_limit="18" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="74"/>
                    <measurement group_id="B5" value="68"/>
                    <measurement group_id="B6" value="65"/>
                    <measurement group_id="B7" value="70"/>
                    <measurement group_id="B8" value="481"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="14"/>
                    <measurement group_id="B8" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="38"/>
                    <measurement group_id="B8" value="245"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="49"/>
                    <measurement group_id="B6" value="55"/>
                    <measurement group_id="B7" value="46"/>
                    <measurement group_id="B8" value="349"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="63"/>
                    <measurement group_id="B6" value="65"/>
                    <measurement group_id="B7" value="66"/>
                    <measurement group_id="B8" value="443"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="17"/>
                    <measurement group_id="B8" value="146"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Rheumatoid Arthritis (RA) duration</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.21" lower_limit="0.5" upper_limit="36.5"/>
                    <measurement group_id="B2" value="7.21" lower_limit="0.6" upper_limit="21.3"/>
                    <measurement group_id="B3" value="7.67" lower_limit="0.6" upper_limit="32.6"/>
                    <measurement group_id="B4" value="8.51" lower_limit="0.5" upper_limit="34.5"/>
                    <measurement group_id="B5" value="8.88" lower_limit="0.5" upper_limit="30.1"/>
                    <measurement group_id="B6" value="7.79" lower_limit="0.5" upper_limit="28.8"/>
                    <measurement group_id="B7" value="9.74" lower_limit="0.5" upper_limit="43.2"/>
                    <measurement group_id="B8" value="8.29" lower_limit="0.5" upper_limit="43.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-reactive protein (CRP) at Baseline</title>
          <units>milligram per liter (mg/L)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.25" lower_limit="1" upper_limit="84.5"/>
                    <measurement group_id="B2" value="27.71" lower_limit="1" upper_limit="158.7"/>
                    <measurement group_id="B3" value="24.54" lower_limit="1" upper_limit="140.7"/>
                    <measurement group_id="B4" value="27.1" lower_limit="1" upper_limit="140.9"/>
                    <measurement group_id="B5" value="26.01" lower_limit="1.2" upper_limit="157.3"/>
                    <measurement group_id="B6" value="24.6" lower_limit="1" upper_limit="113.4"/>
                    <measurement group_id="B7" value="26.86" lower_limit="1" upper_limit="129.4"/>
                    <measurement group_id="B8" value="24.70" lower_limit="1" upper_limit="158.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Corrected tender joint count based on 68 joints (TJC68) at Baseline</title>
          <description>68 joints were assessed for tenderness and joints are classified as tender/not tender giving a total possible tender joint count score of 0 to 68.</description>
          <units>joint count</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.984" lower_limit="8" upper_limit="60"/>
                    <measurement group_id="B2" value="24.907" lower_limit="8" upper_limit="64"/>
                    <measurement group_id="B3" value="25.319" lower_limit="8" upper_limit="68"/>
                    <measurement group_id="B4" value="28.843" lower_limit="8" upper_limit="68"/>
                    <measurement group_id="B5" value="25.427" lower_limit="8" upper_limit="64"/>
                    <measurement group_id="B6" value="27.158" lower_limit="8" upper_limit="66"/>
                    <measurement group_id="B7" value="25.946" lower_limit="7" upper_limit="61"/>
                    <measurement group_id="B8" value="26.091" lower_limit="7" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Corrected swollen joint count based on 66 joints (SJC66) at Baseline</title>
          <description>66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66.</description>
          <units>joint count</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.13" lower_limit="6" upper_limit="48"/>
                    <measurement group_id="B2" value="17.023" lower_limit="6" upper_limit="66"/>
                    <measurement group_id="B3" value="16.31" lower_limit="6" upper_limit="54"/>
                    <measurement group_id="B4" value="17.355" lower_limit="6" upper_limit="58"/>
                    <measurement group_id="B5" value="15.663" lower_limit="6" upper_limit="40"/>
                    <measurement group_id="B6" value="17.534" lower_limit="6" upper_limit="62"/>
                    <measurement group_id="B7" value="16.356" lower_limit="6" upper_limit="48"/>
                    <measurement group_id="B8" value="16.622" lower_limit="6" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving an American College of Rheumatology (ACR) 20 Response at Week 12</title>
        <description>The American College of Rheumatology (ACR) response is a measurement of improvement in multiple disease assessment criteria. The ACR20 response is defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in tender TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain visual analog scale (VAS) (taken from the Health Assessment Questionnaire - Disability Index [HAQ-DI]), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used (ie, to impute a missing response, the participant was assumed to be a non-responder).</description>
        <time_frame>Week 12</time_frame>
        <population>Intent-to-treat (ITT) population included all participants in the safety population who had post-randomization data for at least one efficacy parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received GLPG0634 matching placebo capsules, orally, twice daily (BID) during Weeks 1 to 12. Participants who were responders (having at least 20 percent [%] improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 milligram (mg) once daily (QD) or 50 mg BID during Weeks 13 to 24.</description>
          </group>
          <group group_id="O2">
            <title>GLPG0634 50 mg QD</title>
            <description>Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.</description>
          </group>
          <group group_id="O3">
            <title>GLPG0634 100 mg QD</title>
            <description>Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.</description>
          </group>
          <group group_id="O4">
            <title>GLPG0634 200 mg QD</title>
            <description>Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.</description>
          </group>
          <group group_id="O5">
            <title>GLPG0634 25 mg BID</title>
            <description>Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.</description>
          </group>
          <group group_id="O6">
            <title>GLPG0634 50 mg BID</title>
            <description>Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.</description>
          </group>
          <group group_id="O7">
            <title>GLPG0634 100 mg BID</title>
            <description>Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an American College of Rheumatology (ACR) 20 Response at Week 12</title>
          <description>The American College of Rheumatology (ACR) response is a measurement of improvement in multiple disease assessment criteria. The ACR20 response is defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in tender TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain visual analog scale (VAS) (taken from the Health Assessment Questionnaire - Disability Index [HAQ-DI]), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used (ie, to impute a missing response, the participant was assumed to be a non-responder).</description>
          <population>Intent-to-treat (ITT) population included all participants in the safety population who had post-randomization data for at least one efficacy parameter.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="86"/>
                <count group_id="O6" value="85"/>
                <count group_id="O7" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2"/>
                    <measurement group_id="O2" value="56.1"/>
                    <measurement group_id="O3" value="63.5"/>
                    <measurement group_id="O4" value="68.6"/>
                    <measurement group_id="O5" value="57"/>
                    <measurement group_id="O6" value="60"/>
                    <measurement group_id="O7" value="78.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparisons of each group vs. the placebo group using a logistic regression model with factors treatment group, geographical region, and prior use of biologics.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1236</p_value>
            <method>Regression, Logistic</method>
            <method_desc>P-value has been corrected for multiplicity according to Hommel's closed-testing method.</method_desc>
            <param_type>Difference in percentage rates</param_type>
            <param_value>11.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>26.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparisons of each group vs. the placebo group using a logistic regression model with factors treatment group, geographical region, and prior use of biologics.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0435</p_value>
            <p_value_desc>P-value has been corrected for multiplicity according to Hommel's closed-testing method.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Difference in percentage rates</param_type>
            <param_value>19.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.7</ci_lower_limit>
            <ci_upper_limit>34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparisons of each group vs. the placebo group using a logistic regression model with factors treatment group, geographical region, and prior use of biologics.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0068</p_value>
            <p_value_desc>P-value has been corrected for multiplicity according to Hommel's closed-testing method.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Difference in percentage rates</param_type>
            <param_value>24.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.1</ci_lower_limit>
            <ci_upper_limit>38.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparisons of each group vs. the placebo group using a logistic regression model with factors treatment group, geographical region, and prior use of biologics.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1236</p_value>
            <p_value_desc>P-value has been corrected for multiplicity according to Hommel's closed-testing method.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Difference in percentage rates</param_type>
            <param_value>12.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>27.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparisons of each group vs. the placebo group using a logistic regression model with factors treatment group, geographical region, and prior use of biologics.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1056</p_value>
            <p_value_desc>P-value has been corrected for multiplicity according to Hommel's closed-testing method.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Difference in percentage rates</param_type>
            <param_value>15.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1</ci_lower_limit>
            <ci_upper_limit>30.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparisons of each group vs. the placebo group using a logistic regression model with factors treatment group, geographical region, and prior use of biologics.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>P-value has been corrected for multiplicity according to Hommel's closed-testing method.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Difference in percentage rates</param_type>
            <param_value>34.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.7</ci_lower_limit>
            <ci_upper_limit>48.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an ACR20 Response at Week 24</title>
        <description>ACR20 response was defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used.</description>
        <time_frame>Week 24</time_frame>
        <population>ITT population. Participants who switched treatment at Week 12 were handled as if they discontinued at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received GLPG0634 matching placebo capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20 percent% improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 mg QD or 50 mg BID during Weeks 13 to 24.</description>
          </group>
          <group group_id="O2">
            <title>GLPG0634 50 mg QD</title>
            <description>Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.</description>
          </group>
          <group group_id="O3">
            <title>GLPG0634 100 mg QD</title>
            <description>Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.</description>
          </group>
          <group group_id="O4">
            <title>GLPG0634 200 mg QD</title>
            <description>Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.</description>
          </group>
          <group group_id="O5">
            <title>GLPG0634 25 mg BID</title>
            <description>Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.</description>
          </group>
          <group group_id="O6">
            <title>GLPG0634 50 mg BID</title>
            <description>Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.</description>
          </group>
          <group group_id="O7">
            <title>GLPG0634 100 mg BID</title>
            <description>Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an ACR20 Response at Week 24</title>
          <description>ACR20 response was defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used.</description>
          <population>ITT population. Participants who switched treatment at Week 12 were handled as if they discontinued at Week 12.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="86"/>
                <count group_id="O6" value="85"/>
                <count group_id="O7" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.9"/>
                    <measurement group_id="O2" value="54.9"/>
                    <measurement group_id="O3" value="61.2"/>
                    <measurement group_id="O4" value="73.3"/>
                    <measurement group_id="O5" value="55.8"/>
                    <measurement group_id="O6" value="60"/>
                    <measurement group_id="O7" value="79.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an ACR50 Response at Weeks 1, 2, 4, 8, 12, and 24</title>
        <description>ACR50 response was defined as: 1) ≥ 50% improvement from baseline in SJC66, and 2) ≥ 50% improvement from baseline in TJC68, and 3) ≥ 50% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI) 2. Patient's Global Assessment of Disease Activity VAS 3. Physician's Global Assessment of Disease Activity VAS 4. Total HAQ-DI score 5. CRP. Non-responder imputation was used.</description>
        <time_frame>Weeks 1, 2, 4, 8, 12, and 24</time_frame>
        <population>ITT population. Participants who switched treatment at Week 12 were handled as if they discontinued at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received GLPG0634 matching placebo capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20 percent% improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 mg QD or 50 mg BID during Weeks 13 to 24.</description>
          </group>
          <group group_id="O2">
            <title>GLPG0634 50 mg QD</title>
            <description>Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.</description>
          </group>
          <group group_id="O3">
            <title>GLPG0634 100 mg QD</title>
            <description>Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.</description>
          </group>
          <group group_id="O4">
            <title>GLPG0634 200 mg QD</title>
            <description>Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.</description>
          </group>
          <group group_id="O5">
            <title>GLPG0634 25 mg BID</title>
            <description>Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.</description>
          </group>
          <group group_id="O6">
            <title>GLPG0634 50 mg BID</title>
            <description>Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.</description>
          </group>
          <group group_id="O7">
            <title>GLPG0634 100 mg BID</title>
            <description>Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an ACR50 Response at Weeks 1, 2, 4, 8, 12, and 24</title>
          <description>ACR50 response was defined as: 1) ≥ 50% improvement from baseline in SJC66, and 2) ≥ 50% improvement from baseline in TJC68, and 3) ≥ 50% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI) 2. Patient's Global Assessment of Disease Activity VAS 3. Physician's Global Assessment of Disease Activity VAS 4. Total HAQ-DI score 5. CRP. Non-responder imputation was used.</description>
          <population>ITT population. Participants who switched treatment at Week 12 were handled as if they discontinued at Week 12.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="86"/>
                <count group_id="O6" value="85"/>
                <count group_id="O7" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="4.7"/>
                    <measurement group_id="O4" value="4.7"/>
                    <measurement group_id="O5" value="3.5"/>
                    <measurement group_id="O6" value="7.1"/>
                    <measurement group_id="O7" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="7.3"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="10.5"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="11.8"/>
                    <measurement group_id="O7" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13.4"/>
                    <measurement group_id="O3" value="32.9"/>
                    <measurement group_id="O4" value="17.4"/>
                    <measurement group_id="O5" value="15.1"/>
                    <measurement group_id="O6" value="18.8"/>
                    <measurement group_id="O7" value="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8"/>
                    <measurement group_id="O2" value="26.8"/>
                    <measurement group_id="O3" value="35.3"/>
                    <measurement group_id="O4" value="33.7"/>
                    <measurement group_id="O5" value="25.6"/>
                    <measurement group_id="O6" value="34.1"/>
                    <measurement group_id="O7" value="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1"/>
                    <measurement group_id="O2" value="32.9"/>
                    <measurement group_id="O3" value="37.6"/>
                    <measurement group_id="O4" value="43"/>
                    <measurement group_id="O5" value="27.9"/>
                    <measurement group_id="O6" value="34.1"/>
                    <measurement group_id="O7" value="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3"/>
                    <measurement group_id="O2" value="35.4"/>
                    <measurement group_id="O3" value="47.1"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="34.9"/>
                    <measurement group_id="O6" value="35.3"/>
                    <measurement group_id="O7" value="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an ACR70 Response at Weeks 1, 2, 4, 8, 12, and 24</title>
        <description>ACR70 response: 1) ≥ 70% improvement from baseline in SJC66, and 2) ≥ 70% improvement from baseline in TJC68, and 3) ≥ 70% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used.</description>
        <time_frame>Weeks 1, 2, 4, 8, 12, and 24</time_frame>
        <population>ITT population. Participants who switched treatment at Week 12 were handled as if they discontinued at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received GLPG0634 matching placebo capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20 percent% improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 mg QD or 50 mg BID during Weeks 13 to 24.</description>
          </group>
          <group group_id="O2">
            <title>GLPG0634 50 mg QD</title>
            <description>Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.</description>
          </group>
          <group group_id="O3">
            <title>GLPG0634 100 mg QD</title>
            <description>Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.</description>
          </group>
          <group group_id="O4">
            <title>GLPG0634 200 mg QD</title>
            <description>Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.</description>
          </group>
          <group group_id="O5">
            <title>GLPG0634 25 mg BID</title>
            <description>Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.</description>
          </group>
          <group group_id="O6">
            <title>GLPG0634 50 mg BID</title>
            <description>Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.</description>
          </group>
          <group group_id="O7">
            <title>GLPG0634 100 mg BID</title>
            <description>Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an ACR70 Response at Weeks 1, 2, 4, 8, 12, and 24</title>
          <description>ACR70 response: 1) ≥ 70% improvement from baseline in SJC66, and 2) ≥ 70% improvement from baseline in TJC68, and 3) ≥ 70% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used.</description>
          <population>ITT population. Participants who switched treatment at Week 12 were handled as if they discontinued at Week 12.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="86"/>
                <count group_id="O6" value="85"/>
                <count group_id="O7" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.2"/>
                    <measurement group_id="O5" value="1.2"/>
                    <measurement group_id="O6" value="2.4"/>
                    <measurement group_id="O7" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="7.1"/>
                    <measurement group_id="O4" value="5.8"/>
                    <measurement group_id="O5" value="2.3"/>
                    <measurement group_id="O6" value="5.9"/>
                    <measurement group_id="O7" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="7.3"/>
                    <measurement group_id="O3" value="14.1"/>
                    <measurement group_id="O4" value="4.7"/>
                    <measurement group_id="O5" value="5.8"/>
                    <measurement group_id="O6" value="9.4"/>
                    <measurement group_id="O7" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="23.5"/>
                    <measurement group_id="O4" value="18.6"/>
                    <measurement group_id="O5" value="9.3"/>
                    <measurement group_id="O6" value="14.1"/>
                    <measurement group_id="O7" value="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1"/>
                    <measurement group_id="O2" value="15.9"/>
                    <measurement group_id="O3" value="21.2"/>
                    <measurement group_id="O4" value="24.4"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="18.8"/>
                    <measurement group_id="O7" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="32.9"/>
                    <measurement group_id="O4" value="29.1"/>
                    <measurement group_id="O5" value="20.9"/>
                    <measurement group_id="O6" value="23.5"/>
                    <measurement group_id="O7" value="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR N% Improvement (ACR-N) Response at Weeks 1, 2, 4, 8, 12, and 24</title>
        <description>The ACR-N is the smallest percentage improvement in swollen and tender joints and the median of the remaining 5 core parameters, and is expected to be more sensitive to change than the ACR20, ACR50 or ACR70. It is a number varying between 0 and 100, with higher numbers indicating less severity of symptoms. Last observation carried forward (LOCF) algorithm was used (ie, to impute a missing value, the last preceding nonmissing value was used).</description>
        <time_frame>Weeks 1, 2, 4, 8, 12, and 24</time_frame>
        <population>ITT population with available data were analyzed. Participants who switched treatment at Week 12 were handled as if they discontinued at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received GLPG0634 matching placebo capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20 percent% improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 mg QD or 50 mg BID during Weeks 13 to 24.</description>
          </group>
          <group group_id="O2">
            <title>GLPG0634 50 mg QD</title>
            <description>Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.</description>
          </group>
          <group group_id="O3">
            <title>GLPG0634 100 mg QD</title>
            <description>Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.</description>
          </group>
          <group group_id="O4">
            <title>GLPG0634 200 mg QD</title>
            <description>Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.</description>
          </group>
          <group group_id="O5">
            <title>GLPG0634 25 mg BID</title>
            <description>Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.</description>
          </group>
          <group group_id="O6">
            <title>GLPG0634 50 mg BID</title>
            <description>Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.</description>
          </group>
          <group group_id="O7">
            <title>GLPG0634 100 mg BID</title>
            <description>Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR N% Improvement (ACR-N) Response at Weeks 1, 2, 4, 8, 12, and 24</title>
          <description>The ACR-N is the smallest percentage improvement in swollen and tender joints and the median of the remaining 5 core parameters, and is expected to be more sensitive to change than the ACR20, ACR50 or ACR70. It is a number varying between 0 and 100, with higher numbers indicating less severity of symptoms. Last observation carried forward (LOCF) algorithm was used (ie, to impute a missing value, the last preceding nonmissing value was used).</description>
          <population>ITT population with available data were analyzed. Participants who switched treatment at Week 12 were handled as if they discontinued at Week 12.</population>
          <units>percentage of improvement</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="83"/>
                <count group_id="O6" value="85"/>
                <count group_id="O7" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.27" spread="1.519"/>
                    <measurement group_id="O2" value="10.31" spread="1.578"/>
                    <measurement group_id="O3" value="14.69" spread="2.04"/>
                    <measurement group_id="O4" value="14.25" spread="1.822"/>
                    <measurement group_id="O5" value="9.01" spread="1.603"/>
                    <measurement group_id="O6" value="11.36" spread="1.939"/>
                    <measurement group_id="O7" value="17.63" spread="2.206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.85" spread="1.949"/>
                    <measurement group_id="O2" value="16.36" spread="2.125"/>
                    <measurement group_id="O3" value="25.2" spread="1.986"/>
                    <measurement group_id="O4" value="22.61" spread="2.517"/>
                    <measurement group_id="O5" value="15.2" spread="2.063"/>
                    <measurement group_id="O6" value="20.01" spread="2.47"/>
                    <measurement group_id="O7" value="27.77" spread="2.606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.93" spread="2.332"/>
                    <measurement group_id="O2" value="21.08" spread="2.598"/>
                    <measurement group_id="O3" value="31.32" spread="3.354"/>
                    <measurement group_id="O4" value="27.45" spread="2.573"/>
                    <measurement group_id="O5" value="23.17" spread="2.668"/>
                    <measurement group_id="O6" value="26.37" spread="2.961"/>
                    <measurement group_id="O7" value="35.69" spread="2.861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="2.644"/>
                    <measurement group_id="O2" value="30.16" spread="3.015"/>
                    <measurement group_id="O3" value="38.24" spread="3.484"/>
                    <measurement group_id="O4" value="37.88" spread="3.097"/>
                    <measurement group_id="O5" value="31.2" spread="2.845"/>
                    <measurement group_id="O6" value="33.4" spread="3.15"/>
                    <measurement group_id="O7" value="45.36" spread="3.246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.09" spread="2.911"/>
                    <measurement group_id="O2" value="34.03" spread="3.335"/>
                    <measurement group_id="O3" value="39.87" spread="3.449"/>
                    <measurement group_id="O4" value="42.1" spread="3.277"/>
                    <measurement group_id="O5" value="34.12" spread="3.144"/>
                    <measurement group_id="O6" value="35.86" spread="3.29"/>
                    <measurement group_id="O7" value="51.17" spread="3.379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.06" spread="2.846"/>
                    <measurement group_id="O2" value="37.13" spread="3.582"/>
                    <measurement group_id="O3" value="50.86" spread="3.645"/>
                    <measurement group_id="O4" value="50.4" spread="3.291"/>
                    <measurement group_id="O5" value="38.56" spread="3.384"/>
                    <measurement group_id="O6" value="40.5" spread="3.299"/>
                    <measurement group_id="O7" value="58.69" spread="3.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Disease Activity Score 28 Joints Corrected for CRP (DAS28 (CRP)) European League Against Rheumatism (EULAR) Response at Weeks 1, 2, 4, 8, 12, and 24</title>
        <description>DAS28 (CRP) was categorized into EULAR response categories (none, moderate, good) as follows: None = Actual DAS28 (CRP) ≤ 3.2, &gt; 3.2 to ≤ 5.1, or &gt; 5.1 AND Improvement in DAS28 (CRP) from baseline ≤ 6.0 or &gt; 0.6 to ≤ 1.2; Moderate = Actual DAS28 (CRP) ≤ 3.2 AND Improvement in DAS28 (CRP) from baseline &gt; 0.6 to ≤ 1.2, Actual DAS28 (CRP) &gt; 3.2 to ≤ 5.1 or &gt; 5.1 AND Improvement in DAS28 (CRP) from baseline &gt; 1.2, or Actual DAS28 (CRP) &gt; 3.2 to ≤ 5.1 AND Improvement in DAS28 (CRP) from baseline &gt; 0.6 to ≤ 1.2; Good = Actual DAS28 (CRP) ≤ 3.2 AND Improvement in DAS28 (CRP) from baseline &gt; 1.2. LOCF algorithm was used.</description>
        <time_frame>Weeks 1, 2, 4, 8, 12, and 24</time_frame>
        <population>ITT population. Participants who switched treatment at Week 12 were handled as if they discontinued at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received GLPG0634 matching placebo capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20 percent% improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 mg QD or 50 mg BID during Weeks 13 to 24.</description>
          </group>
          <group group_id="O2">
            <title>GLPG0634 50 mg QD</title>
            <description>Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.</description>
          </group>
          <group group_id="O3">
            <title>GLPG0634 100 mg QD</title>
            <description>Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.</description>
          </group>
          <group group_id="O4">
            <title>GLPG0634 200 mg QD</title>
            <description>Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.</description>
          </group>
          <group group_id="O5">
            <title>GLPG0634 25 mg BID</title>
            <description>Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.</description>
          </group>
          <group group_id="O6">
            <title>GLPG0634 50 mg BID</title>
            <description>Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.</description>
          </group>
          <group group_id="O7">
            <title>GLPG0634 100 mg BID</title>
            <description>Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Disease Activity Score 28 Joints Corrected for CRP (DAS28 (CRP)) European League Against Rheumatism (EULAR) Response at Weeks 1, 2, 4, 8, 12, and 24</title>
          <description>DAS28 (CRP) was categorized into EULAR response categories (none, moderate, good) as follows: None = Actual DAS28 (CRP) ≤ 3.2, &gt; 3.2 to ≤ 5.1, or &gt; 5.1 AND Improvement in DAS28 (CRP) from baseline ≤ 6.0 or &gt; 0.6 to ≤ 1.2; Moderate = Actual DAS28 (CRP) ≤ 3.2 AND Improvement in DAS28 (CRP) from baseline &gt; 0.6 to ≤ 1.2, Actual DAS28 (CRP) &gt; 3.2 to ≤ 5.1 or &gt; 5.1 AND Improvement in DAS28 (CRP) from baseline &gt; 1.2, or Actual DAS28 (CRP) &gt; 3.2 to ≤ 5.1 AND Improvement in DAS28 (CRP) from baseline &gt; 0.6 to ≤ 1.2; Good = Actual DAS28 (CRP) ≤ 3.2 AND Improvement in DAS28 (CRP) from baseline &gt; 1.2. LOCF algorithm was used.</description>
          <population>ITT population. Participants who switched treatment at Week 12 were handled as if they discontinued at Week 12.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="86"/>
                <count group_id="O6" value="85"/>
                <count group_id="O7" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1: None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="42"/>
                    <measurement group_id="O5" value="63"/>
                    <measurement group_id="O6" value="64"/>
                    <measurement group_id="O7" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="55"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="32"/>
                    <measurement group_id="O7" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1: Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="51"/>
                    <measurement group_id="O6" value="44"/>
                    <measurement group_id="O7" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="53"/>
                    <measurement group_id="O5" value="43"/>
                    <measurement group_id="O6" value="46"/>
                    <measurement group_id="O7" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="37"/>
                    <measurement group_id="O6" value="35"/>
                    <measurement group_id="O7" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="65"/>
                    <measurement group_id="O5" value="44"/>
                    <measurement group_id="O6" value="42"/>
                    <measurement group_id="O7" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="22"/>
                    <measurement group_id="O7" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="24"/>
                    <measurement group_id="O7" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="49"/>
                    <measurement group_id="O5" value="51"/>
                    <measurement group_id="O6" value="49"/>
                    <measurement group_id="O7" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="27"/>
                    <measurement group_id="O7" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="55"/>
                    <measurement group_id="O5" value="44"/>
                    <measurement group_id="O6" value="56"/>
                    <measurement group_id="O7" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="37"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="28"/>
                    <measurement group_id="O7" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="14"/>
                    <measurement group_id="O7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="37"/>
                    <measurement group_id="O6" value="49"/>
                    <measurement group_id="O7" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="51"/>
                    <measurement group_id="O5" value="40"/>
                    <measurement group_id="O6" value="36"/>
                    <measurement group_id="O7" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving ACR/EULAR Remission at Weeks 2, 4, 8, 12, and 24</title>
        <description>A participant's disease activity status can be defined as being in remission when scores on the TJC28, SJC28, CRP (actual value in mg/dL) and Patient Global Assessment of Disease Activity (cm) are all ≤ 1. Non-responder imputation was used.</description>
        <time_frame>Weeks 2, 4, 8, 12, and 24</time_frame>
        <population>ITT population. Participants who switched treatment at Week 12 were handled as if they discontinued at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received GLPG0634 matching placebo capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20 percent% improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 mg QD or 50 mg BID during Weeks 13 to 24.</description>
          </group>
          <group group_id="O2">
            <title>GLPG0634 50 mg QD</title>
            <description>Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.</description>
          </group>
          <group group_id="O3">
            <title>GLPG0634 100 mg QD</title>
            <description>Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.</description>
          </group>
          <group group_id="O4">
            <title>GLPG0634 200 mg QD</title>
            <description>Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.</description>
          </group>
          <group group_id="O5">
            <title>GLPG0634 25 mg BID</title>
            <description>Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.</description>
          </group>
          <group group_id="O6">
            <title>GLPG0634 50 mg BID</title>
            <description>Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.</description>
          </group>
          <group group_id="O7">
            <title>GLPG0634 100 mg BID</title>
            <description>Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving ACR/EULAR Remission at Weeks 2, 4, 8, 12, and 24</title>
          <description>A participant's disease activity status can be defined as being in remission when scores on the TJC28, SJC28, CRP (actual value in mg/dL) and Patient Global Assessment of Disease Activity (cm) are all ≤ 1. Non-responder imputation was used.</description>
          <population>ITT population. Participants who switched treatment at Week 12 were handled as if they discontinued at Week 12.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="86"/>
                <count group_id="O6" value="85"/>
                <count group_id="O7" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3.5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="1.2"/>
                    <measurement group_id="O4" value="2.3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="3.7"/>
                    <measurement group_id="O3" value="3.5"/>
                    <measurement group_id="O4" value="3.5"/>
                    <measurement group_id="O5" value="1.2"/>
                    <measurement group_id="O6" value="1.2"/>
                    <measurement group_id="O7" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="3.7"/>
                    <measurement group_id="O3" value="3.5"/>
                    <measurement group_id="O4" value="5.8"/>
                    <measurement group_id="O5" value="4.7"/>
                    <measurement group_id="O6" value="4.7"/>
                    <measurement group_id="O7" value="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8.2"/>
                    <measurement group_id="O4" value="11.6"/>
                    <measurement group_id="O5" value="5.8"/>
                    <measurement group_id="O6" value="3.5"/>
                    <measurement group_id="O7" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 1, 2, 4, 8, 12, and 24</title>
        <description>The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, Patient Global Assessment of Disease Activity (in cm), Physician's Global Assessment of Disease Activity (in cm), and CRP (mg/dL). The SDAI was categorized as follows:&#xD;
• High disease activity: SDAI &gt; 26 • Moderate disease activity: 11 to 26 • Low disease activity: 3.3 to 11 • Remission: ≤ 3.3. LOCF algorithm was used. The SDAI total score ranges from 0 to approximately 86.</description>
        <time_frame>Baseline and Weeks 1, 2, 4, 8, 12, and 24</time_frame>
        <population>ITT population with available data were analyzed. Participants who switched treatment at Week 12 were handled as if they discontinued at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received GLPG0634 matching placebo capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20 percent% improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 mg QD or 50 mg BID during Weeks 13 to 24.</description>
          </group>
          <group group_id="O2">
            <title>GLPG0634 50 mg QD</title>
            <description>Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.</description>
          </group>
          <group group_id="O3">
            <title>GLPG0634 100 mg QD</title>
            <description>Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.</description>
          </group>
          <group group_id="O4">
            <title>GLPG0634 200 mg QD</title>
            <description>Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.</description>
          </group>
          <group group_id="O5">
            <title>GLPG0634 25 mg BID</title>
            <description>Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.</description>
          </group>
          <group group_id="O6">
            <title>GLPG0634 50 mg BID</title>
            <description>Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.</description>
          </group>
          <group group_id="O7">
            <title>GLPG0634 100 mg BID</title>
            <description>Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 1, 2, 4, 8, 12, and 24</title>
          <description>The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, Patient Global Assessment of Disease Activity (in cm), Physician's Global Assessment of Disease Activity (in cm), and CRP (mg/dL). The SDAI was categorized as follows:&#xD;
• High disease activity: SDAI &gt; 26 • Moderate disease activity: 11 to 26 • Low disease activity: 3.3 to 11 • Remission: ≤ 3.3. LOCF algorithm was used. The SDAI total score ranges from 0 to approximately 86.</description>
          <population>ITT population with available data were analyzed. Participants who switched treatment at Week 12 were handled as if they discontinued at Week 12.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="86"/>
                <count group_id="O6" value="85"/>
                <count group_id="O7" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="86"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.756" spread="1.2717"/>
                    <measurement group_id="O2" value="43.77" spread="1.3499"/>
                    <measurement group_id="O3" value="45.42" spread="1.3909"/>
                    <measurement group_id="O4" value="45.611" spread="1.3362"/>
                    <measurement group_id="O5" value="43.951" spread="1.3224"/>
                    <measurement group_id="O6" value="44.794" spread="1.4043"/>
                    <measurement group_id="O7" value="44.542" spread="1.3097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" spread="1.25"/>
                    <measurement group_id="O2" value="-8" spread="1.14"/>
                    <measurement group_id="O3" value="-12.2" spread="1.45"/>
                    <measurement group_id="O4" value="-12.8" spread="1.29"/>
                    <measurement group_id="O5" value="-8.2" spread="1.17"/>
                    <measurement group_id="O6" value="-10" spread="1.22"/>
                    <measurement group_id="O7" value="-14.5" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.4" spread="1.45"/>
                    <measurement group_id="O2" value="-12.5" spread="1.46"/>
                    <measurement group_id="O3" value="-18.6" spread="1.64"/>
                    <measurement group_id="O4" value="-16.4" spread="1.35"/>
                    <measurement group_id="O5" value="-13.4" spread="1.29"/>
                    <measurement group_id="O6" value="-15.1" spread="1.43"/>
                    <measurement group_id="O7" value="-20.3" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.1" spread="1.47"/>
                    <measurement group_id="O2" value="-16.3" spread="1.64"/>
                    <measurement group_id="O3" value="-22.7" spread="1.78"/>
                    <measurement group_id="O4" value="-22.2" spread="1.28"/>
                    <measurement group_id="O5" value="-17.8" spread="1.44"/>
                    <measurement group_id="O6" value="-19.3" spread="1.74"/>
                    <measurement group_id="O7" value="-24.9" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.3" spread="1.64"/>
                    <measurement group_id="O2" value="-20.1" spread="1.86"/>
                    <measurement group_id="O3" value="-24.6" spread="1.57"/>
                    <measurement group_id="O4" value="-25.9" spread="1.57"/>
                    <measurement group_id="O5" value="-22.2" spread="1.68"/>
                    <measurement group_id="O6" value="-23.2" spread="1.8"/>
                    <measurement group_id="O7" value="-29.2" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.3" spread="1.84"/>
                    <measurement group_id="O2" value="-21" spread="1.84"/>
                    <measurement group_id="O3" value="-25.2" spread="1.69"/>
                    <measurement group_id="O4" value="-27.2" spread="1.55"/>
                    <measurement group_id="O5" value="-22.3" spread="1.71"/>
                    <measurement group_id="O6" value="-24.5" spread="1.87"/>
                    <measurement group_id="O7" value="-30.6" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.8" spread="2"/>
                    <measurement group_id="O2" value="-22.8" spread="2.07"/>
                    <measurement group_id="O3" value="-30.1" spread="1.66"/>
                    <measurement group_id="O4" value="-31" spread="1.66"/>
                    <measurement group_id="O5" value="-24.9" spread="1.85"/>
                    <measurement group_id="O6" value="-27.9" spread="2"/>
                    <measurement group_id="O7" value="-34.4" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 1, 2, 4, 8, 12, and 24</title>
        <description>The CDAI is the SDAI modified to exclude CRP and is the sum of the 4 outcome parameters: TJC28, SJC28, Patient Global Assessment of Disease Activity (in cm), and Physician's Global Assessment of Disease Activity (in cm). The CDAI was be categorized as follows: • High disease activity: &gt; 22 • Moderate disease activity: 10 to 22 • Mild disease activity: 2.8 to 10 • Remission: ≤ 2.8. LOCF algorithm was used. The CDAI total score ranges from 0 to approximately 76.</description>
        <time_frame>Baseline and Weeks 1, 2, 4, 8, 12, and 24</time_frame>
        <population>ITT population with available data were analyzed. Participants who switched treatment at Week 12 were handled as if they discontinued at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received GLPG0634 matching placebo capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20 percent% improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 mg QD or 50 mg BID during Weeks 13 to 24.</description>
          </group>
          <group group_id="O2">
            <title>GLPG0634 50 mg QD</title>
            <description>Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.</description>
          </group>
          <group group_id="O3">
            <title>GLPG0634 100 mg QD</title>
            <description>Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.</description>
          </group>
          <group group_id="O4">
            <title>GLPG0634 200 mg QD</title>
            <description>Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.</description>
          </group>
          <group group_id="O5">
            <title>GLPG0634 25 mg BID</title>
            <description>Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.</description>
          </group>
          <group group_id="O6">
            <title>GLPG0634 50 mg BID</title>
            <description>Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.</description>
          </group>
          <group group_id="O7">
            <title>GLPG0634 100 mg BID</title>
            <description>Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 1, 2, 4, 8, 12, and 24</title>
          <description>The CDAI is the SDAI modified to exclude CRP and is the sum of the 4 outcome parameters: TJC28, SJC28, Patient Global Assessment of Disease Activity (in cm), and Physician's Global Assessment of Disease Activity (in cm). The CDAI was be categorized as follows: • High disease activity: &gt; 22 • Moderate disease activity: 10 to 22 • Mild disease activity: 2.8 to 10 • Remission: ≤ 2.8. LOCF algorithm was used. The CDAI total score ranges from 0 to approximately 76.</description>
          <population>ITT population with available data were analyzed. Participants who switched treatment at Week 12 were handled as if they discontinued at Week 12.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="86"/>
                <count group_id="O6" value="85"/>
                <count group_id="O7" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="86"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.131" spread="1.236"/>
                    <measurement group_id="O2" value="40.999" spread="1.2104"/>
                    <measurement group_id="O3" value="42.966" spread="1.3014"/>
                    <measurement group_id="O4" value="42.901" spread="1.2844"/>
                    <measurement group_id="O5" value="41.347" spread="1.2442"/>
                    <measurement group_id="O6" value="42.333" spread="1.3186"/>
                    <measurement group_id="O7" value="41.856" spread="1.2462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="1.23"/>
                    <measurement group_id="O2" value="-7.2" spread="1.09"/>
                    <measurement group_id="O3" value="-11.1" spread="1.38"/>
                    <measurement group_id="O4" value="-11.1" spread="1.22"/>
                    <measurement group_id="O5" value="-7.3" spread="1.14"/>
                    <measurement group_id="O6" value="-9" spread="1.15"/>
                    <measurement group_id="O7" value="-12.8" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.6" spread="1.43"/>
                    <measurement group_id="O2" value="-11.7" spread="1.39"/>
                    <measurement group_id="O3" value="-17.3" spread="1.58"/>
                    <measurement group_id="O4" value="-14.6" spread="1.29"/>
                    <measurement group_id="O5" value="-12.4" spread="1.26"/>
                    <measurement group_id="O6" value="-14" spread="1.38"/>
                    <measurement group_id="O7" value="-18.4" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.3" spread="1.42"/>
                    <measurement group_id="O2" value="-15.2" spread="1.54"/>
                    <measurement group_id="O3" value="-21.4" spread="1.71"/>
                    <measurement group_id="O4" value="-20.4" spread="1.24"/>
                    <measurement group_id="O5" value="-17.1" spread="1.35"/>
                    <measurement group_id="O6" value="-18" spread="1.71"/>
                    <measurement group_id="O7" value="-22.8" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.4" spread="1.58"/>
                    <measurement group_id="O2" value="-18.9" spread="1.78"/>
                    <measurement group_id="O3" value="-23.4" spread="1.52"/>
                    <measurement group_id="O4" value="-24.2" spread="1.15"/>
                    <measurement group_id="O5" value="-21.1" spread="1.67"/>
                    <measurement group_id="O6" value="-21.9" spread="1.75"/>
                    <measurement group_id="O7" value="-27.1" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.6" spread="1.84"/>
                    <measurement group_id="O2" value="-19.7" spread="1.77"/>
                    <measurement group_id="O3" value="-23.8" spread="1.66"/>
                    <measurement group_id="O4" value="-25.5" spread="1.5"/>
                    <measurement group_id="O5" value="-21.3" spread="1.65"/>
                    <measurement group_id="O6" value="-23.2" spread="1.81"/>
                    <measurement group_id="O7" value="-28.5" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16" spread="1.95"/>
                    <measurement group_id="O2" value="-21.3" spread="1.97"/>
                    <measurement group_id="O3" value="-28.6" spread="1.63"/>
                    <measurement group_id="O4" value="-29.4" spread="1.5"/>
                    <measurement group_id="O5" value="-23.8" spread="1.75"/>
                    <measurement group_id="O6" value="-26.7" spread="1.9"/>
                    <measurement group_id="O7" value="-32.4" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life Using the Functional Assessment of Chronic Illness Therapy (FACIT) at Weeks 4, 12, and 24</title>
        <description>FACIT-Fatigue scale is a 13-item questionnaire, each scored on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated that are scored reversely), the greater the fatigue. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score), with a higher score indicating a better quality of life. LOCF algorithm was used.</description>
        <time_frame>Baseline and Weeks 4, 12, and 24</time_frame>
        <population>ITT population with available data were analyzed. Participants who switched treatment at Week 12 were handled as if they discontinued at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received GLPG0634 matching placebo capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20 percent% improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 mg QD or 50 mg BID during Weeks 13 to 24.</description>
          </group>
          <group group_id="O2">
            <title>GLPG0634 50 mg QD</title>
            <description>Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.</description>
          </group>
          <group group_id="O3">
            <title>GLPG0634 100 mg QD</title>
            <description>Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.</description>
          </group>
          <group group_id="O4">
            <title>GLPG0634 200 mg QD</title>
            <description>Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.</description>
          </group>
          <group group_id="O5">
            <title>GLPG0634 25 mg BID</title>
            <description>Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.</description>
          </group>
          <group group_id="O6">
            <title>GLPG0634 50 mg BID</title>
            <description>Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.</description>
          </group>
          <group group_id="O7">
            <title>GLPG0634 100 mg BID</title>
            <description>Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life Using the Functional Assessment of Chronic Illness Therapy (FACIT) at Weeks 4, 12, and 24</title>
          <description>FACIT-Fatigue scale is a 13-item questionnaire, each scored on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated that are scored reversely), the greater the fatigue. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score), with a higher score indicating a better quality of life. LOCF algorithm was used.</description>
          <population>ITT population with available data were analyzed. Participants who switched treatment at Week 12 were handled as if they discontinued at Week 12.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="86"/>
                <count group_id="O6" value="85"/>
                <count group_id="O7" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="86"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" spread="1.09"/>
                    <measurement group_id="O2" value="26.2" spread="1.1"/>
                    <measurement group_id="O3" value="26.6" spread="1.06"/>
                    <measurement group_id="O4" value="25.2" spread="1.25"/>
                    <measurement group_id="O5" value="28.1" spread="1.18"/>
                    <measurement group_id="O6" value="26.2" spread="1.04"/>
                    <measurement group_id="O7" value="25.6" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="86"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="1.06"/>
                    <measurement group_id="O2" value="4.4" spread="1.11"/>
                    <measurement group_id="O3" value="9.1" spread="1.14"/>
                    <measurement group_id="O4" value="8.5" spread="1.23"/>
                    <measurement group_id="O5" value="4.5" spread="1.06"/>
                    <measurement group_id="O6" value="6.6" spread="0.88"/>
                    <measurement group_id="O7" value="9.9" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="86"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="1.06"/>
                    <measurement group_id="O2" value="7.6" spread="1.26"/>
                    <measurement group_id="O3" value="9.5" spread="1.21"/>
                    <measurement group_id="O4" value="11.4" spread="1.37"/>
                    <measurement group_id="O5" value="6.9" spread="1.12"/>
                    <measurement group_id="O6" value="8.4" spread="1.08"/>
                    <measurement group_id="O7" value="11.3" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="86"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="1.04"/>
                    <measurement group_id="O2" value="7.9" spread="1.21"/>
                    <measurement group_id="O3" value="11.1" spread="1.2"/>
                    <measurement group_id="O4" value="11.6" spread="1.33"/>
                    <measurement group_id="O5" value="7.7" spread="1.17"/>
                    <measurement group_id="O6" value="9" spread="1.04"/>
                    <measurement group_id="O7" value="12.8" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life Using the Short Form-36 (SF-36) Scores at Weeks 4, 12, and 24</title>
        <description>The SF-36 is a 36-item questionnaire measuring 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health). Each domain score ranges from 0 (worst) to 100 (best), with higher scores reflecting better health-related functional status. Two summary scale scores were computed based on weighted combinations of the 8 domain scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). LOCF algorithm was used.</description>
        <time_frame>Baseline and Weeks 4, 12, and 24</time_frame>
        <population>ITT population with available data were analyzed. Participants who switched treatment at Week 12 were handled as if they discontinued at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received GLPG0634 matching placebo capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20 percent% improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 mg QD or 50 mg BID during Weeks 13 to 24.</description>
          </group>
          <group group_id="O2">
            <title>GLPG0634 50 mg QD</title>
            <description>Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.</description>
          </group>
          <group group_id="O3">
            <title>GLPG0634 100 mg QD</title>
            <description>Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.</description>
          </group>
          <group group_id="O4">
            <title>GLPG0634 200 mg QD</title>
            <description>Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.</description>
          </group>
          <group group_id="O5">
            <title>GLPG0634 25 mg BID</title>
            <description>Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.</description>
          </group>
          <group group_id="O6">
            <title>GLPG0634 50 mg BID</title>
            <description>Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.</description>
          </group>
          <group group_id="O7">
            <title>GLPG0634 100 mg BID</title>
            <description>Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life Using the Short Form-36 (SF-36) Scores at Weeks 4, 12, and 24</title>
          <description>The SF-36 is a 36-item questionnaire measuring 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health). Each domain score ranges from 0 (worst) to 100 (best), with higher scores reflecting better health-related functional status. Two summary scale scores were computed based on weighted combinations of the 8 domain scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). LOCF algorithm was used.</description>
          <population>ITT population with available data were analyzed. Participants who switched treatment at Week 12 were handled as if they discontinued at Week 12.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="86"/>
                <count group_id="O6" value="85"/>
                <count group_id="O7" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCS at Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="86"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.999" spread="0.7121"/>
                    <measurement group_id="O2" value="32.691" spread="0.7474"/>
                    <measurement group_id="O3" value="31.636" spread="0.7926"/>
                    <measurement group_id="O4" value="31.625" spread="0.6355"/>
                    <measurement group_id="O5" value="31.364" spread="0.6858"/>
                    <measurement group_id="O6" value="31.332" spread="0.726"/>
                    <measurement group_id="O7" value="32.249" spread="0.7844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="86"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="0.65"/>
                    <measurement group_id="O2" value="4.1" spread="0.88"/>
                    <measurement group_id="O3" value="6.1" spread="0.98"/>
                    <measurement group_id="O4" value="6.4" spread="0.87"/>
                    <measurement group_id="O5" value="5" spread="0.69"/>
                    <measurement group_id="O6" value="4.2" spread="0.8"/>
                    <measurement group_id="O7" value="7.2" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="86"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.74"/>
                    <measurement group_id="O2" value="6.7" spread="1"/>
                    <measurement group_id="O3" value="8.4" spread="0.93"/>
                    <measurement group_id="O4" value="8.9" spread="0.9"/>
                    <measurement group_id="O5" value="7.5" spread="0.92"/>
                    <measurement group_id="O6" value="7.1" spread="0.96"/>
                    <measurement group_id="O7" value="10.5" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="86"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.75"/>
                    <measurement group_id="O2" value="7.3" spread="1.02"/>
                    <measurement group_id="O3" value="9.9" spread="1.09"/>
                    <measurement group_id="O4" value="9.7" spread="0.99"/>
                    <measurement group_id="O5" value="7.8" spread="0.85"/>
                    <measurement group_id="O6" value="7.9" spread="0.91"/>
                    <measurement group_id="O7" value="11.6" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS at Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="86"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.849" spread="1.0861"/>
                    <measurement group_id="O2" value="42.199" spread="1.2581"/>
                    <measurement group_id="O3" value="43.953" spread="1.1118"/>
                    <measurement group_id="O4" value="41.362" spread="1.1427"/>
                    <measurement group_id="O5" value="45.527" spread="1.288"/>
                    <measurement group_id="O6" value="44.748" spread="1.228"/>
                    <measurement group_id="O7" value="42.059" spread="1.2898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="86"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="0.92"/>
                    <measurement group_id="O2" value="3.4" spread="0.91"/>
                    <measurement group_id="O3" value="4.9" spread="0.85"/>
                    <measurement group_id="O4" value="5.4" spread="0.98"/>
                    <measurement group_id="O5" value="2.4" spread="0.78"/>
                    <measurement group_id="O6" value="2.7" spread="0.84"/>
                    <measurement group_id="O7" value="5.6" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="86"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="1.05"/>
                    <measurement group_id="O2" value="4.4" spread="1.11"/>
                    <measurement group_id="O3" value="5.1" spread="0.96"/>
                    <measurement group_id="O4" value="8.1" spread="1.17"/>
                    <measurement group_id="O5" value="3.5" spread="0.97"/>
                    <measurement group_id="O6" value="3.1" spread="1.02"/>
                    <measurement group_id="O7" value="6.2" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="86"/>
                    <count group_id="O6" value="85"/>
                    <count group_id="O7" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="0.96"/>
                    <measurement group_id="O2" value="4.3" spread="1.04"/>
                    <measurement group_id="O3" value="6.7" spread="0.91"/>
                    <measurement group_id="O4" value="7.2" spread="1.12"/>
                    <measurement group_id="O5" value="3.8" spread="0.96"/>
                    <measurement group_id="O6" value="3.5" spread="1.01"/>
                    <measurement group_id="O7" value="7.1" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline through end of study drug treatment (average exposure: 160.7 days) plus 10 days</time_frame>
      <desc>Nonresponders from Placebo (15 participants), 50 mg QD (19 participants) moved to 100 mg QD group and nonresponders from Placebo (15 participants) and 25 mg BID (17 participants) moved to 50 mg BID group from Week 13 to Week 24.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received GLPG0634 matching placebo capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20 percent% improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 mg QD or 50 mg BID during Weeks 13 to 24.</description>
        </group>
        <group group_id="E2">
          <title>GLPG0634 50 mg QD</title>
          <description>Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.</description>
        </group>
        <group group_id="E3">
          <title>GLPG0634 100 mg QD</title>
          <description>Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.</description>
        </group>
        <group group_id="E4">
          <title>GLPG0634 200 mg QD</title>
          <description>Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.</description>
        </group>
        <group group_id="E5">
          <title>GLPG0634 25 mg BID</title>
          <description>Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.</description>
        </group>
        <group group_id="E6">
          <title>GLPG0634 50 mg BID</title>
          <description>Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.</description>
        </group>
        <group group_id="E7">
          <title>GLPG0634 100 mg BID</title>
          <description>Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must review and approve any results of the study or abstracts for professional meetings prepared by the investigator(s). Published data must not compromise the objectives of the study. Data from individual study centers in multicenter studies must not be published separately.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Information Desk</name_or_title>
      <organization>Galapagos N.V.</organization>
      <phone>+32 (0)15 342 900</phone>
      <email>rd@glpg.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

